Amy Brockmeyer, MD
Gynecologic Oncology · Seattle, WANPI 1891959862
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,450 of the $4,202 with a category attached, or 82.1%. AstraZeneca accounts for 85.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $3,450 and has fallen 94.3% since, to $196 in 2025.
Across 17 payments — averaging $247.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Intuitive Surgical$259
- GSK$125
- Aadi Bioscience, Inc.$100
- Sanofi$27
- Novartis$24
- plus $66 from 4 others
What the payments were for
- Consulting fees$3,45082%
- Food & beverage$75218%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $3,601 |
| Intuitive Surgical | 3 | $259 |
| GSK | 1 | $125 |
| Aadi Bioscience, Inc. | 1 | $100 |
| Sanofi | 2 | $27 |
| Novartis | 2 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| Bayer | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$3,450
- Da Vinci Surgical System$237
- JEMPERLI$125
How this compares
$4,202 in reported general payments places this provider in the 75th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 20 | $2,003 |
| Dexamethasone | 12 | $193 |
| Prochlorperazine Maleate | 16 | $146 |
| Ondansetron Hcl | 15 | $103 |
| Oxycodone Hcl | 21 | $95 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Seattle
- Chirag ShahSeattle$732K
- Fernanda MusaSeattle$120K
- Bobbie RimelSeattle$41K
- Nicole FlemingSeattle$20K
- Renata UrbanSeattle$7K
- Amy BondurantSeattle$2K
- Kathryn PenningtonSeattle$2K
- Soledad JorgeSeattle$1K
- Elise SimonsSeattle$459
- Allison BarrieSeattle$428
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.